Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P-Reference-Cited by-同舟云学术

Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P

Published:2006-01-01 Issue:12 Volume:47 Page:2488-2504
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Nathan Paul C.¹,Whitcomb Trish¹,Wolters Pamela L.¹²,Steinberg Seth M.³,Balis Frank M.¹,Brouwers Pim¹,Hunsberger Sally⁴,Feusner James⁵,Sather Harland⁶,Miser James⁷,Odom Lorrie F.⁸,Poplack David¹,Reaman Gregory⁹,Bleyer W. Archie¹⁰

Affiliation:

1. Pediatric Oncology Branch

2. Medical Illness Counseling Center, Bethesda, MD

3. Biostatistics and Data Management Section and HIV & AIDS Malignancy Branch18, Center for Cancer Research

4. Biostatistics Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

5. Children's Hospital of Northern California, Oakland, CA

6. Children's Oncology Group, Arcadia, CA

7. Columbus Children's Hospital, Columbus, OH

8. Denver Children's Hospital, Denver, CO

9. Children's National Medical Center, Washington, DC, USA

10. Children's Regional Medical Center, Seattle, WA

Publisher